论文部分内容阅读
目的探讨替吉奥静脉联合腹腔治疗方案在胃癌腹水中的临床疗效。方法选取2010年9月—2012年9月遵化市人民医院治疗的胃癌并发腹水的90名患者为研究对象,随机分为观察组(替吉奥联合静脉和腹腔化疗组)45例,对照组(传统疗法组)45例,观察替吉奥联合静脉和腹腔化疗方案在胃癌腹水中的临床应用疗效。结果观察组2例腹水量为重度,比例为4.44%,明显低于对照组15.56%,两组比较差异有统计学意义(P<0.05);观察组治疗后39例为有效,占86.67%,明显高于对照组(62.22%),两组比较差异有统计学意义(P<0.05)。结论替吉奥联合静脉和腹腔化疗方案治疗胃癌并发腹水,效果较好,可以推广。
Objective To investigate the clinical efficacy of tegaserod combined with intraperitoneal chemotherapy in ascites of gastric cancer. Methods Ninety patients with gastric cancer complicated with ascites treated in Zunhua People’s Hospital from September 2010 to September 2012 were selected and randomly divided into observation group (45 cases) and control group (45 cases) (Traditional therapy group) 45 cases, observed for the combination of intravenous and intragastric chemotherapy for ascites in patients with gastric cancer clinical efficacy. Results In the observation group, the ascites volume in 2 cases was severe (4.44%), which was significantly lower than that in the control group (15.56%), with significant difference between the two groups (P <0.05). In the observation group, 39 cases were effective, accounting for 86.67% Significantly higher than the control group (62.22%), the difference between the two groups was statistically significant (P <0.05). Conclusion Treatment of gastric cancer with ascites combined with intravenous and intraperitoneal chemotherapy is better and can be promoted.